Want to see HRGN full AI Analyst Report?
Top Page
Harvard Apparatus Regenerative Technology
(OTC:HRGN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-45.05% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by very weak financial performance (minimal revenue, severe losses, and ongoing cash burn with a significantly eroded equity base). Technicals are mixed with only modest near-term improvement and a still-weak longer-term trend. Corporate events provide some pipeline progress, but near-term financing needs temper the outlook, while valuation is constrained by losses (negative P/E) and no dividend support.
Positive Factors
Clinical Milestone / Pipeline Progress
Treating the first patient in an FDA‑regulated Phase 1 trial is a durable program de‑risking event: it validates clinical feasibility, advances regulatory pathway work, and materially progresses the lead program toward later trials or partnerships, strengthening long‑term value drivers.
Negative Factors
Sustained Negative Cash Flow
Persistent negative operating and free cash flow consume balance‑sheet resources and force ongoing external financing. This structural cash burn creates execution risk for multi‑site clinical programs and raises the probability that development timelines will depend on successful future raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Milestone / Pipeline Progress
Treating the first patient in an FDA‑regulated Phase 1 trial is a durable program de‑risking event: it validates clinical feasibility, advances regulatory pathway work, and materially progresses the lead program toward later trials or partnerships, strengthening long‑term value drivers.
Read all positive factors
Harvard Apparatus Regenerative Technology (HRGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.81M
Dividend YieldN/A
Average Volume (3M)1.13K
Price to Earnings (P/E)―
Beta (1Y)-0.26
Revenue Growth111.72%
EPS Growth17.33%
CountryUS
Employees8
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,580,744
10 Day Avg. Volume797
30 Day Avg. Volume1,125
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)28.75
Price to Sales (P/S)43.17
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue41.72
Enterprise Value/Gross Profit-49.64
Enterprise Value/Ebitda-2.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Harvard Apparatus Regenerative Technology Business Overview & Revenue Model
Company Description
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal sy...
How the Company Makes Money
null...
Harvard Apparatus Regenerative Technology Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 445.00K | 704.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -374.00K | 58.00K | -270.00K | -24.00K | 0.00 | 0.00 |
| EBITDA | -6.70M | -6.76M | -8.16M | -9.09M | -5.92M | -8.53M |
| Net Income | -6.81M | -6.87M | -7.73M | -9.02M | -6.07M | -7.98M |
Balance Sheet | ||||||
| Total Assets | 1.80M | 2.68M | 4.44M | 2.61M | 2.40M | 1.87M |
| Cash, Cash Equivalents and Short-Term Investments | 419.00K | 1.35M | 2.49M | 432.00K | 1.24M | 1.24M |
| Total Debt | 173.00K | 199.00K | 294.00K | 48.00K | 147.00K | 169.00K |
| Total Liabilities | 1.71M | 1.62M | 1.22M | 968.00K | 1.41M | 4.89M |
| Stockholders Equity | 92.00K | 1.06M | 3.22M | 1.65M | 989.00K | -3.03M |
Cash Flow | ||||||
| Free Cash Flow | -4.01M | -3.83M | -4.85M | -6.95M | -5.11M | -2.63M |
| Operating Cash Flow | -4.01M | -3.83M | -4.85M | -6.94M | -5.11M | -2.63M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -11.00K | -5.00K | 0.00 |
| Financing Cash Flow | 2.70M | 2.70M | 6.91M | 6.14M | 5.06M | 2.84M |
Harvard Apparatus Regenerative Technology Technical Analysis
Negative
1.82
Price Trends
1.25
Negative
1.46
Negative
1.65
Negative
Market Momentum
-0.06
Positive
40.84
Neutral
23.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Negative. The current price of 1.82 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.25, and above the 200-day MA of 1.65, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 23.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HRGN.
Harvard Apparatus Regenerative Technology Risk Analysis
Harvard Apparatus Regenerative Technology disclosed 49 risk factors in its most recent earnings report. Harvard Apparatus Regenerative Technology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Harvard Apparatus Regenerative Technology Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
53 Neutral | $270.68M | 8.16 | -0.29% | ― | -100.00% | 72.96% | |
51 Neutral | $11.21M | -0.08 | ― | ― | ― | 80.65% | |
47 Neutral | $6.17M | -1.37 | -79.47% | ― | -100.00% | 62.88% | |
45 Neutral | $18.81M | -2.55 | -344.15% | ― | 111.72% | 17.33% | |
45 Neutral | $32.74M | -1.90 | -101.90% | ― | -83.00% | 19.02% | |
45 Neutral | $19.65M | -0.52 | -119.92% | ― | -45.35% | 58.32% |
* Consumer Defensive Sector Average
HRGN
Harvard Apparatus Regenerative Technology
1.07
-0.36
-24.91%
LSTA
Lisata Therapeutics
3.53
0.94
36.63%
MBRX
Moleculin Biotech
2.14
-17.92
-89.33%
PULM
Pulmatrix
1.68
-4.39
-72.32%
SABS
SAB Biotherapeutics
3.51
0.81
30.00%
LGVN
Longeveron
0.60
-1.08
-64.17%
Harvard Apparatus Regenerative Technology Corporate Events
Business Operations and StrategyProduct-Related Announcements
Harvard Apparatus Begins First Cellspan Esophageal Implant Trial
Positive
Apr 28, 2026
On April 27, 2026, Harvard Apparatus Regenerative Technology announced that the first patient has been treated with its Cellspan Esophageal Implant in a Phase 1 feasibility and safety clinical trial at the Mayo Clinic in Rochester, Minnesota. This...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.